JNJ Contact Lens Approval Masks Stock Valuation Concerns

Johnson & Johnson (NYSE: JNJ) has received CE Marking approval for its new ACUVUE OASYS MAX 2-Week contact lens, marking a significant milestone in its medical device innovation pipeline. The company plans to launch the product in select European markets later this year, with broader expansion expected in 2027 and 2028 pending regulatory approvals and market readiness.

The CE Marking approval underscores JNJ's ongoing commitment to innovative medicines and advanced medtech products. With a strong fundamental profile reflected in its GF Score of 83/100, the company operates primarily through its pharmaceutical and medical devices divisions following the divestment of its consumer health business, Kenvue, in 2023.

Despite the company's attractive dividend metrics, including a yield of 1.98% and a payout ratio of 50%, JNJ's stock price currently trades at $267.08-38.3% above its GF Value of $193.18. This valuation premium suggests that the market may be pricing in strong future growth and stability, but it also indicates limited margin of safety for new investors at current levels.

Insider activity shows significant net selling over the past 12 months, with insiders offloading $154.9 million worth of shares versus minimal buying. GuruFocus tracks 24 premium gurus holding JNJ shares, reflecting broad institutional confidence in the company's long-term prospects. However, recent activity shows a net trimming trend, with 14 gurus reducing their positions compared to only 5 adding shares.